Blood
Articles in this Issue
The chromatin accessibility landscape of pediatric AML
Antiaging for Ph-like ALL: targeting senescence
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
Abstract Outcomes are poor in patients with higher-risk myelodysplastic syndromes (HR MDS) and frontline treatment options are limited. This phase 1b study investigated safety and ef...
Selenoprotein-mediated redox regulation shapes the cell fate of HSCs and mature lineages
Abstract The maintenance of cellular redox balance is crucial for cell survival and homeostasis and is disrupted with aging. Selenoproteins, comprising essential antioxidant enzymes,...
Low counts count after CAR-T for ALL
Heat-insoluble cryoglobulin in peripheral blood
Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia
Abstract Immune effector cell–associated hematotoxicity (ICAHT) is a major B-cell targeted chimeric antigen receptor (CAR) T-cell related toxicity....
Why is InO’s divine veil not protective against resistance?
Honing CAR T cells to tackle acute myeloid leukemia
Abstract Acute myeloid leukemia (AML) remains a dismal disease with poor prognosis, particularly in the relapsed/refractory (R/R) setting. Chimeric antigen receptor (CAR) therapy has...
Targeting senescent stemlike subpopulations in Philadelphia chromosome–like acute lymphoblastic leukemia
Abstract Philadelphia chromosome–like B-cell acute lymphoblastic leukemia (Ph-like ALL) is driven by genetic alterations that induce constitutive kinase signaling and is associated w...
Single-cell epigenetic and clonal analysis decodes disease progression in pediatric acute myeloid leukemia
Abstract Pediatric acute myeloid leukemia (pAML) is a clonal disease with recurrent genetic alterations that affect epigenetic states. However, the implications of epigenetic dysregu...
Make hematopoiesis great again: countering oxidative stress!
Azacitidine and venetoclax for HR-MDS: election results pending
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia
Abstract Inotuzumab ozogamicin (InO) is an antibody-calicheamicin conjugate with striking efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, there is wide interpatient...
The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma
Abstract Immunomodulatory drugs (IMiDs) are a major class of drugs for treating multiple myeloma (MM); however, acquired resistance to IMiDs remains a significant clinical challenge....